Psoriasis
Conference Coverage
Secukinumab tames psoriatic arthritis in FUTURE 2 trial
Key clinical point: Secukinumab could prove to be a major new therapy for psoriatic arthritis. Major finding: After 24 weeks, a response of at...
Conference Coverage
Few psoriatic arthritis patients achieve minimal disease activity on methotrexate
Key clinical point: It may be time to rethink methotrexate’s role as first-line therapy for psoriatic arthritis. Major finding: Only 17.4% of...
News
TNF-alpha blockers effective in sustaining reduced PsA activity
Key clinical point: A majority of PsA patients seen in a clinical setting can achieve minimal disease activity on TNF-alpha inhibitors. Major...
Conference Coverage
Psoriasis is independently associated with advanced liver fibrosis
Key clinical point: Noninvasive screening for advanced hepatic fibrosis may be in order for older patients with mild psoriasis never treated...
News
Psoriasis: Brodalumab maintains efficacy through 144 weeks
Key clinical point: The investigational interleukin-17 receptor A inhibitor brodalumab maintained strong clinical efficacy throughout 144 weeks of...
Article
The Top 100
In the October 2014 issue of the Journal of Clinical and Aesthetic Dermatology (2014;7:10-19), Wu et al published the top 100 most-cited...
Conference Coverage
Certolizumab achieves sustained skin improvement in psoriatic arthritis
Key clinical point: Certolizumab pegol maintains sustained improvement in the dermatologic manifestations of psoriatic arthritis through 96 weeks...
News
Oral curcumin shown effective in psoriasis
Key clinical point: A common ingredient in Indian curry spice mixes is safe and effective as adjuvant therapy for mild-to-moderate psoriasis.
News
Chronic inflammatory disease patients at greater risk of major CV events
Key clinical point: Patients with RA, PsA, and psoriasis have similarly elevated risk for major adverse cardiovascular events when compared with...
Clinical Topics & News
Recent Findings About Plaque Psoriasis
Recent articles in the literature to further the dermatologist’s understanding of plaque psoriasis.